Delivery Order SPE2DE24D0013-SPE2D626F13F2
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order valued at $23,120 to Cepheid Inc. on November 13, 2025, with an ultimate completion date of November 20, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic reagents and test kits for detecting COVID-19, influenza, and respiratory syncytial virus. The work will be performed at Cepheid's headquarters in Sunnyvale, California. This award carries no set-aside designation,...
- The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a firm fixed-price delivery order valued at $8,160 on October 28, 2025, for diagnostic reagents and test kits related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, designated XPCOV2/FLU/RSV-10, carries an ultimate completion date of November 4, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. This award utilizes no set-aside designation,...
- The Defense Logistics Agency Medical Supply Chain awarded a $13,600 firm fixed-price delivery order to Cepheid Inc. on November 4, 2025, with an ultimate completion date of November 12, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing supplies and reagents for detecting COVID-19, influenza, and respiratory syncytial virus. Cepheid, headquartered in Sunnyvale, California, is a leading federal supplier of advanced molecular diagnostic systems and...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, was awarded a $4,080 firm fixed-price delivery order by the Defense Logistics Agency Medical Supply Chain on November 10, 2025, with an ultimate completion date of November 18, 2025. The delivery order, designated 4569971783 and titled XPCOV2/FLU/RSV-10, procures diagnostic testing supplies and reagents for detecting COVID-19, influenza, and respiratory syncytial virus (RSV). This award carries...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain office, awarded a firm fixed-price delivery order valued at $8,840 to Cepheid Inc. on July 29, 2025, with an ultimate completion date of August 5, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing solutions, specifically reagents and test kits for detecting COVID-19, influenza, and respiratory syncytial virus (RSV). The contract carries no set-aside designation and will be...
- The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a $14,037.50 firm fixed-price delivery order on November 3, 2025, for the Kit Xpert Xpress COVID-19, Flu, RSV + Molecular Biology diagnostic testing supplies. The contract, which is not subject to any set-aside designation, has an ultimate completion date of November 10, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. This delivery order represents a continuation of DLA Medical Supply Chain's...
- On December 5, 2025, the Defense Logistics Agency's Medical Supply Chain issued a firm fixed-price delivery order valued at $7,537.85 to Cepheid Inc. for respiratory diagnostic reagents and test kits under the contract designation XPCOV2/FLU/RSV-10. The delivery order, with an ultimate completion date of December 12, 2025, will be performed at Cepheid's headquarters in Sunnyvale, California. This award carries no set-aside designation and represents a continuation of the federal government's...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain program, awarded a $8,995.14 firm fixed-price delivery order to Cepheid Inc. on May 6, 2025, for molecular diagnostic solutions with an ultimate completion date of May 13, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, references testing capabilities for COVID-19, influenza, and respiratory syncytial virus (RSV)—aligning with Cepheid's core diagnostic product offerings. The contract carries no set-aside...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to Cepheid Inc. for $2,040 on November 17, 2025, with an ultimate completion date of November 24, 2025. This firm fixed-price delivery order, identified as XPCOV2/FLU/RSV-10, represents a procurement of molecular diagnostic testing supplies, specifically reagents and test kits for the detection of COVID-19, influenza, and respiratory syncytial virus using Cepheid's GeneXpert diagnostic platform. The contract contains no...
- The Defense Logistics Agency Medical Supply Chain awarded a $14,960 firm fixed-price delivery order to Cepheid Inc. on November 20, 2025, with an ultimate completion date of December 5, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, represents a relatively modest procurement within Cepheid's broader federal contracting portfolio and likely involves molecular diagnostic reagents or test cartridges for detecting COVID-19, influenza, and respiratory syncytial virus using Cepheid's...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D626F13F2Delivery Order
The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a $11,987 firm fixed-price delivery order on December 11, 2025, with an ultimate completion date of December 18, 2025. The delivery order, identified as XPCOV2/FLU/RSV-10, is for molecular diagnostic reagents and test kits designed for the GeneXpert diagnostic platform, specifically supporting the detection of COVID-19, influenza, and respiratory syncytial virus (RSV). This award was made without a set-aside designation and will be performed at Cepheid's headquarters location in Sunnyvale, California. The contract reflects the company's established role as a primary federal supplier of rapid molecular diagnostic testing solutions across multiple defense and civilian healthcare agencies. Cepheid has demonstrated substantial capability in supplying diagnostic solutions throughout the federal healthcare system, particularly through extensive contracts with the Department of Veterans Affairs, which include two significant indefinite delivery contracts valued at over $39 million combined through 2030. The company's GeneXpert diagnostic platform and associated molecular testing capabilities have become foundational to infectious disease detection operations across the VA's medical centers, the Defense Health Agency, Indian Health Service, and U.S. Coast Guard facilities. This delivery order represents a routine procurement under DLA Medical Supply Chain's broader procurement operations supporting federal healthcare diagnostic requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 12/10/25 |